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Summary
Objective: We studied the accumulation of parathyroid hormone (PTH)/PTHrP receptor-positive mesenchymal cells using double immunohis-
tochemistry and examined whether this correlated with the subsequent regeneration of 3-mm-diameter full-thickness defects of articular
cartilage.
Materials and methods: Cylindrical full-thickness articular cartilage defects (3 mm) were artiﬁcially created in the femoral trochlea of male
adolescent Japanese white rabbits (n¼ 210) with a hand-drill. Recombinant human PTH(1e84) was then administered into the defect cavities
with an osmotic pump for either 2 or 4 weeks post-injury. Following PTH treatment, the repair processes in the cartilage defects were histo-
logically examined. Double immunostaining analyses for the PTH/PTH-related peptide (PTHrP) receptor and proliferating cell nuclear antigen
(PCNA) in the regenerating tissues were then performed.
Results: Activation of PTH/PTHrP receptor signaling by hPTH(1e84) results in the inhibition of chondrogenic differentiation in full-thickness
articular cartilage defects. At the conclusion of the 2-week PTH treatment, the defect cavities were ﬁlled with undifferentiated mesenchymal
cells, which were similar to the controls. In addition, almost all of these cells localized at the center of the injuries were both PTH/PTHrP
receptor- and PCNA-positive. In contrast, after prolonged PTH treatment for 4 weeks, there was no indication of a cartilaginous repair response
and cells that had migrated to the defect cavities were found to have irreversibly lost expression of the PTH/PTHrP receptor.
Conclusions: The chondrogenic capacity of cells that had migrated to the area of these defect cavities is closely associated with their ability to
express the PTH/PTHrP receptor. Moreover, these cells maintain their chondrogenic potential within only a limited time-span of 2 weeks.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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It has been now well established that bone marrow contains
stem cells that can differentiate into multiple mesenchymal
lineages1,2. In full-thickness defects that are created by
the penetration of articular cartilage, marrow-derived undif-
ferentiated cells migrate into the defect cavities within
a few days, and these cells are thought to serve as precur-
sors for subsequent repair responses1. There is also grow-
ing evidence to suggest that various signaling molecules
regulate chondrogenic differentiation during the repair
process of full-thickness defects of articular cartilage3e6.
Moreover, the reparative response to such defects largely
depends on their size3,4.
In a rabbit model of smaller cylindrical defects (3 mm in
diameter) created in the femoral trochlea, undifferentiated
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to regenerate the epiphyseal morphology. This includes
repair of the surface articular cartilage and of the subchon-
dral bone up to the original boneearticular cartilage junc-
tion. In larger defects (5 mm in diameter), by contrast,
chondrogenesis does not occur and these cavities are ﬁlled by
ﬁbrous tissue. Taking advantage of this model, we have
previously demonstrated that ﬁbroblast growth factor-2
(FGF-2) effectively stimulates both the mobilization and
migration of replicating mesenchymal cells, thus functioning in
support of a chondrogenic repair response to full-thickness
defects of articular cartilage4,7,8.
Parathyroid hormone (PTH)/PTH-related peptide (PTHrP)
receptor signaling has been shown to inhibit the exit of
proliferating chondrocytes from the cell cycle and to nega-
tively regulate the progression of the late-phase dif-
ferentiation of chondrocytes during endochondral bone
formation9e14. The activation of PTH/PTHrP receptors has
been also shown to inhibit the conversion of proliferating
chondrocytes into hypertrophic and calcifying chondrocytes
in culture15. In addition, the overproduction of PTHrP in
proliferating chondrocytes delays their late-phase44
945Osteoarthritis and Cartilage Vol. 14, No. 9differentiation in transgenic mice13. However, the respon-
siveness to PTH/PTHrP is concomitantly acquired with the
chondrogenic induction (or early-phase differentiation) of
chondroprogenitor cells at the stage of mesenchymal con-
densation, prior to overt chondrogenesis. Furthermore, the
expression of PTH/PTHrP receptors has been demonstrated
to begin at this early stage and to augment as chondrogenic
differentiation progresses16e18.
In 3-mm-diameter full-thickness cartilage defects, immu-
noreactivity to the PTH/PTHrP receptor protein can be
detected in cells that migrate into the defect cavities at 1
week after injury and prior to cartilage formation19. In a pre-
vious study in this laboratory, we demonstrated for the ﬁrst
time that PTH/PTHrP signaling has inhibitory effects upon
early-phase chondrogenic differentiation of mesenchymal
cells in vivo19. In addition, the activation of PTH/PTHrP sig-
naling by human PTH(1e84) markedly inhibited cartilage
regeneration in 3-mm-diameter full-thickness defects of
articular cartilage in rabbit. In our current study we as-
sessed the accumulation of PTH/PTHrP receptor-positive
proliferating mesenchymal cells in these same defects in
the rabbit by double immunohistochemistry, and correlated
this with subsequent cartilage regeneration. We demon-
strate in particular that the initial stages of repair in this sys-
tem are perturbed by a temporal administration of PTH.
Materials and methods
CREATION OF FULL-THICKNESS DEFECTS OF ARTICULAR
CARTILAGE IN RABBITS
Male adolescent Japanese white rabbits (n¼ 210),
weighing from 3 to 3.4 kg, were anesthetized with sodium
pentobarbital (30 mg/kg bodyweight intravenously). The
right knee joint was then opened using a medial parapatel-
lar approach under sterile conditions and the patella was
dislocated laterally to expose the articular surface of the
femoral trochlea. Full-thickness defects (3 mm in diameter;
4 mm in depth) were created in the weight-bearing area of
the femoral trochlea with a hand-drill equipped with
a 3-mm-diameter drill-bit, as described previously4,19. For
some experiments, 5-mm-diameter full-thickness defects
(4 mm in depth) were similarly created. All animals were
allowed to walk freely without a splint. Our research protocol
was approved by the animal ethics committee of Kumamoto
University School of Medicine, and animal care and exper-
imental procedures were conducted in accordance with
institutional guidelines (http://card.medic.kumamoto-u.ac.
jp/card/japanese/kisoku/kisoku.html).
ADMINISTRATION OF PTH AND FGF-2
Recombinant human parathyroid hormone 1e84 (hPTH
(1e84)) was expressed and puriﬁed from Escherichia coli
by high-performance liquid chromatography using a cleav-
able fusion protein strategy as previously described20.
Puriﬁed hPTH(1e84) prepared in this way was supplied
by Chugai Pharmaceuticals (Tokyo, Japan) for the present
study. The animals were ﬁtted with an osmotic pump (Alzet,
Model 2002, Alza Corp., Palo Alto, CA, USA) connected to
silastic medical grade tubing (0.75 mm inside diameter/
1.45 mm outside diameter). A 5 mm long piece of tubing
was then introduced into the articular knee cavity through
the articular capsule. The osmotic pump was placed subcu-
taneously in the hind region of the leg and the articular
capsule and skin were closed independently with 4e0 nylon
sutures4,19.Sixty rabbits that were given 3-mm-diameter defects were
evenly divided into three experimental groups (n¼ 20); one
group was treated with PTH for 2 weeks after injury (2-week
PTH-treated group), one group was treated with PTH for 4
weeks after injury (4-week PTH-treated group) and we
analyzed an untreated control group. For the 40 PTH-
treated animals, the osmotic pumps were ﬁlled with 200 ml
of sterile saline containing hPTH(1e84) at a concentration of
50 mg/ml and had a nominal pumping rate of 0.5 ml/h for
a 2-week period. In both the 2- and 4-week PTH-treated
groups, the pumps were removed after 2 weeks, but in
the case of the 4-week group these were replaced. The
20 control animals received sterile saline only with the
same osmotic pump system. For all subsequent histochem-
ical and immunohistochemical analyses, the animals were
sacriﬁced post-injury at 1, 2, 4, and 8 weeks for the control
group, at 2, 4, 6, and 10 weeks for the 2-week PTH-treated
group and at 4, 6, 8, and 12 weeks for the 4-week PTH-
treated group.
For comparison, larger full-thickness defects of 5 mm in
diameter and 4 mm in depth were also generated in a further
10 rabbits4,7. For ﬁve of these animals, the ﬁtted osmotic
pump (nominal pumping rate of 0.5 ml/h) had been previ-
ously ﬁlled with 100 ml of sterile saline containing human
recombinant FGF-2 (Takeda Chemical Industries, Osaka,
Japan; 0.1 mg/ml). These were designated as the FGF-2
treated group. The remaining ﬁve animals received sterile
saline alone and were the control group. At 1 week post-
injury, each of the rabbits was sacriﬁced for subsequent
immunohistochemical analysis. Three sets of experiments
were performed using a total of 210 rabbits and yielded sim-
ilar and reproducible results.
HISTOLOGICAL AND IMMUNOHISTOCHEMICAL ANALYSES
Five animals from each study group were sacriﬁced at
each time point with an overdose of sodium pentobarbital
(Fig. 1). The distal portion of each femur was then ﬁxed in
4% paraformaldehyde at room temperature for 1 h, decalci-
ﬁed with 10% ethylenediaminetetraacetic acid (EDTA) for 3
weeks and then embedded in parafﬁn for subsequent
histological analysis. To examine the sequential repair
processes in each cavity, 5 mm transverse sections were
Fig. 1. Experimental design for the PTH treatment of 3-mm-diame-
ter full-thickness defects of articular cartilage. Five animals in each
group were sacriﬁced at the indicated times (D). The distal portion
of each femur was removed, ﬁxed as described in Materials and
methods, and subjected to histological analysis.
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ysis of the reparative tissue, the sections were examined
in a blinded manner by two observers not informed on the
group assignment, and were scored according to the histo-
logical grading scale of Pineda et al., with some modiﬁca-
tions (Table I)21. The scale used here is inversely
correlated to the original one so that better recovery of artic-
ular structure has a higher score; the score ranges from
0 (worst) to 14 (best)4.
To assess the expression of the PTH/PTHrP receptor in
non-chondrocytic spindle-shaped cells in the defects, we
performed immunostaining at 1 and 2 weeks in the control
group, at 2 and 4 weeks in the 2-week PTH-treated group
and at 4, 6, 8, and 12 weeks in the 4-week PTH-treated
group. Each section were cut, deparafﬁnized and hydrated
and endogenous peroxidase activity was blocked with 0.5%
H2O2 in methanol, followed by washing with 0.1% bovine
serum albumin (BSA) in Tris-buffered saline (TBS). The
sections were then treated with 500 U/ml testicular hyal-
uronidase22. Non-speciﬁc staining was reduced by incuba-
tion with horse serum. The sections were then incubated
with a monoclonal antibody against the opossum
PTH/PTHrP receptor (dilution 1:100; BabCo, Richmond,
CA, USA) overnight at 4(C. As we previously reported19,
the speciﬁcity and cross-reactivity of this antibody to rabbit
PTH/PTHrP receptor could be conﬁrmed by preliminary
experiments using rabbit kidney and growth plate as a posi-
tivecontrol and rabbit prostateand thyroidglandasanegative
control23e25. The samples were then treated with the Vectas-
tain avidinebiotineperoxidase complex (ABC) kit (Vector
Laboratories, Burlingame, CA, USA), reacted with diamino-
benzidine (DAB) solution and then counterstained with
methyl green. For negative controls, the sections were incu-
batedwith either horse serumor puriﬁed non-immunemouse
IgG (Sigma Chemical Co., St. Louis, MO, USA).
Table I
Scoring system for the histological appearance of full-thickness
defects of articular cartilage*
Characteristics Score
Filling of defects (%)
125 3
100 4
75 3
50 2
25 1
0 0
Reconstitution of osteochondral junction
Yes 2
Almost 1
Not close 0
Matrix staining
Normal 4
Reduced staining 3
Signiﬁcant staining 2
Faint staining 1
No staining 0
Cell morphology
Normal 4
Mostly hyaline and ﬁbrocartilage 3
Mostly ﬁbrocartilage 2
Some ﬁbrocartilage, but mostly non-chondrocytic cells 1
Non-chondrocytic cell only 0
Perfect score 14
*Modiﬁed from Pineda et al. (1992)21.To assess if there is any correlation between PTH/PTHrP
receptor expression in non-chondrocytic spindle-shaped
cells and their proliferative capacity, we performed double
immunostaining for PTH/PTHrP receptor and proliferating
cell nuclear antigen (PCNA) at 1 week in the control group,
at 2 weeks in the 2-week PTH-treated group and at 4, 6, 8
and 12 weeks in the 4-week PTH-treated group (Fig. 1).
Parafﬁn sections were ﬁrst immunostained for PTH/PTHrP
receptor as described above, washed in 0.1% BSA in
TBS and incubated with a monoclonal antibody against
PCNA (dilution 1:100; Dakopatts, Copenhagen, Denmark)
at room temperature for 1 h. The slides were then washed
in 0.1% BSA in TBS and incubated with alkaline phospha-
tase (ALP) conjugated secondary antibody (dilution 1:100;
Sigma, St. Louis, MO, USA) for 1 h. The color development
of the ALP reaction was carried out using an ALP substrate
kit I (Vector Red; Vector Laboratories, Burlingame, CA,
USA). Levamisole (1 mM) (Vector Laboratories, Burlin-
game, CA, USA) was added to block endogenous ALP
activities. The sections were then counterstained with he-
matoxylin. Negative controls for each immunostaining
experiment were incubated either with a secondary anti-
body alone or with puriﬁed non-immune mouse IgG (Sigma
Chemical Co., St. Louis, MO, USA).
QUANTITATIVE ANALYSIS OF CO-LOCALIZATION OF PCNA
AND PTH/PTHrP RECEPTOR
To determine whether PTH/PTHrP receptor expression in
non-chondrocytic spindle-shaped cells is related to PCNA
expression, these cells were analyzed in the defect cavities
and divided into four sub-types: PTH/PTHrP receptor
single-positive, PCNA single-positive, PTH/PTHrP recep-
tor/PCNA double-positive and double-negative cells. Each
sub-type was quantiﬁed according to the method of Aizawa
and expressed as the percentage of the total number of
cells in the defects12. A section of each defect was then
divided into 12 sampling square areas (1 mm 1 mm) in
which ﬁve ﬁelds were selected at a magniﬁcation of 400.
Because three sections from each parafﬁn bloc were
used, the numbers of each of the four sub-types of spin-
dle-shaped cells were determined in a total of 180 ﬁelds
for each animal. The incidence of each cell type in each
case of the reparative tissue was expressed as the
meanSD for ﬁve animals from each experimental group.
Sections were examined in a blind manner and statistical
signiﬁcance was estimated using the ManneWhitney’s U
test. A P value of <0.05 was considered statistically
signiﬁcant.
Results
EFFECTS OF PTH ON THE REPAIR OF FULL-THICKNESS
ARTICULAR CARTILAGE DEFECTS IN RABBIT
Using an adolescent rabbit model, we previously estab-
lished that small cylindrical full-thickness articular cartilage
defects of 3 mm in diameter spontaneously resurfaced
with hyaline cartilage within 8e12 weeks post-injury4,7.
This occurred through the chondrogenic differentiation of
mesenchymal cells which had initially ﬁlled the defect cav-
ity. Thus, in the control 3-mm-diameter defects adminis-
tered with saline alone, the cavities were mainly ﬁlled by
spindle-shaped mesenchymal cells at one week post-injury
[Fig. 2(A); see also Fig. 4(A) at higher magniﬁcation]. In
addition, the synthesis of woven bone had progressed near
to the surface of subchondral bone in the depths of these
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defects. The defects were treated with saline alone (AeD), with 25 ng/h hPTH (1e84) for the initial 2 weeks post-injury (EeH) and for the initial
4 weeks post-injury (IeL). The distal portion of each femur was cut in the transverse plane and the sections were stained with safranin-O at (A)
1 week, (B and E) 2 weeks, (C, F, and I) 4 weeks, (G and J) 6 weeks, (D and K) 8 weeks, (H) 10 weeks and (L) 12 weeks. Bar, 500 mm.cartilage defects. At 2 weeks post-injury, the ﬁrst evidence
of cartilage formation was observed in the central region
of the cavities [Fig. 2(B); see also Fig. 4(B) at higher
magniﬁcation]. The cells in question showed a spherical or
polygonal morphology and were surrounded by safranin-
O-positive extracellular matrix. At 4 weeks post-injury, carti-
lage formation was evident in the upper half of the defects
[Fig. 2(C)]. Furthermore, chondrocytes deep within the
cartilage layer were found to have undergone typical endo-
chondral differentiation. At 8 weeks, the defects were
reconstituted and resurfaced with hyaline-like articular carti-
lage [Fig. 2(D)]. The thickness of the cartilage layer was
restored to an extent that was similar to the thickness of the
adjacent normal articular cartilage, as a result of the resto-
ration of subchondral bone up to the original boneearticular
cartilage junction. In addition to the regeneration of articular
cartilage, a total histological score of these defects showed
a detectable increasewithin 2weeks post-injury and reached
almost maximal levels at 8 weeks (Fig. 3)19.
The cavities that had been administered with 25 ng/ml
hPTH(1e84) for the initial 2 weeks after they were gener-
ated contained only spindle-shaped mesenchymal cells,
even at the conclusion of the PTH treatment [Fig. 2(E);
see also Fig. 4(E) at higher magniﬁcation]. Although new
woven bone formation had already commenced in the
depths of these defects, no safranin-O-positive cartilagi-
nous tissue was observed to have formed, except in the
marginal area. The reparative tissue appeared in this
case to be essentially similar to the regenerating tissue dur-
ing the early stages in the cavities of the control animals
[Fig. 2(A)]. At 4 weeks (2 weeks after the cessation of
PTH treatment), cartilaginous tissue had formed in the cen-
tral region of the defects, as indicated by the appearance ofFig. 3. Timecourse of histological scores (Table I) for the cartilag-
inous regeneration of the 3-mm-diameter articular cartilage
defects. After creation of the defects, the cavities were treated
with saline alone for the initial 4 weeks post-injury (,), or treated
with 25 ng/h hPTH (1e84) for the initial 2 (>) or 4 weeks post-
injury (B). The values shown are the meansSD (n¼ 5) of the
scores from histological sections of ﬁve individual animals. Three
independent experiments were performed and yielded similar
results.
948 H. Mizuta et al.: PTH/PTHrP receptor expression in chondrogenic cellsFig. 4. Immunohistochemical analyses of PTH/PTHrP receptor expression in the reparative tissue of the articular cartilage defects, with or
without the 25 ng/h hPTH (1e84) treatment. The 3-mm-diamter defects were treated with saline alone (A and B), or with 25 ng/h hPTH
(1e84) for the initial 2 weeks (E and F) or 4 weeks (IeL) post-injury. Animals were sacriﬁced at the indicated times. The panels represent
the immunostaining pattern of PTH/PTHrP receptor expression in the reparative tissues denoted by asterisks in the corresponding A, B, E,
F, I, J, K, and L panels in Fig. 2. The sections were counterstained with methyl green. Bar, 50 mm.spherical or polygonal cells located in lacunae surrounded
by safranin-O-positive extracellular matrix [Fig. 2(F); see
also Fig. 4(F) at higher magniﬁcation]. The regenerated car-
tilaginous tissue was gradually replaced by subchondral
bone through an endochondral sequence until the original
boneearticular junction was restored [Fig. 2(G)]. At 10
weeks (8 weeks after the cessation of PTH administration),
the defects had reconstituted an epiphyseal morphology,
including articular cartilage and subchondral bone [Fig. 2(H)].
As shown in Fig. 3, the total histological scores in this group
at 4 weeks post-injury were as low as the control group at 2
weeks. However, at 10 weeks post-injury, these scores
reached a maximal level equivalent to the controls. More-
over, a timecourse experiment that evaluated these scores
indicated that the regenerative processes of cartilage
renewal had been delayed by the period of the 2-week PTH
treatment (Fig. 3).
In the 4-week PTH-treated group, the defect cavities con-
tained non-chondrocytic spindle-shaped cells at 4 weeks
post-injury [Fig. 2(I); see also Fig. 4(I) at higher magniﬁca-
tion]. Furthermore, safranin-O stained cartilage matrix was
not observed in these defects. Reconstitution of the sub-
chondral bone in the depths of the cavities in this group
was also hampered by continuous PTH administration,
consistent with our previous report19. Signiﬁcantly, the ap-
pearance of the defects after 4 weeks of PTH administration
was histologically equivalent to the control group at 1 week
post-injury [Fig. 2(A and I)]. Moreover, even after the dis-
continuation of PTH treatment, none of the cavities hadbeen resurfaced with safranin-O-positive cartilaginous tis-
sue [Fig. 2(J, K and L)]. There was no evidence of chondro-
genic differentiation in this 4-week PTH group, even after 12
weeks, except in the marginal areas near subchondral
bone. Furthermore, at 12 weeks post-injury in this group,
cells ﬁlling the defects retained a spindle-shaped morphol-
ogy, although the subchondral bone was almost fully recon-
stituted [Fig. 2(L)]. A timecourse analysis of the histological
score in this group produced low values during the entire
period of the experiment (Fig. 3), although the successful
regeneration of subchondral bone contributed to a slight
increase in these calculations.
EXPRESSION OF THE PTH/PTHRP RECEPTOR
IN THE REGENERATING TISSUE OF ARTICULAR
CARTILAGE DEFECTS
Figure 4 shows immunostaining of the PTH/PTHrP recep-
tor in spindle-shaped mesenchymal cells ﬁlling the defect
cavities, using an antibody against the opossum PTH/
PTHrP receptor19. Each of the panels in Fig. 4 represents
serial sections showing PTH/PTHrP receptor immunostain-
ing at the center of the regenerating tissue, denoted by the
asterisks in the corresponding panels A, B, E, F, I, J, K, and
L in Fig. 2. The speciﬁcity of the PTH/PTHrP antibody was
demonstrated by the negative control staining of a section
with preimmune mouse IgG instead of the PTH/PTHrP
receptor antibody, as previously reported19. In the control
group, most of the non-chondrocytic spindle-shaped
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[Fig. 4(A)]. At 2 weeks post-injury in the control defect
group, the spindle-shaped cells around the regenerating
chondrocytes and beneath the surfacing area were also
expressing PTH/PTHrP receptor [Fig. 4(B)]. In the 2-week
PTH-treated group, PTH/PTHrP receptor expression was
widely detected in most of the non-chondrocytic spindle-
shaped cells at the end of the PTH treatment [Fig. 4(E)].
At 4 weeks post-injury in this group, this PTH/PTHrP
expression persisted in the surfacing area [Fig. 4(F)]. In
contrast, in the 4-week PTH-treated group, PTH/PTHrP
receptor expression could not be detected at the center or
surface of the cavities at the end of the PTH administration
period [Fig. 4(I)]. Only a few PTH/PTHrP receptor-positive
cells were observed in marginal areas near subchondral
bone of the defects in this group. Moreover, PTH/PTHrP
receptor expression did not recover even after 8 weeks fol-
lowing the cessation of PTH treatment [Fig. 4(J, K, and L)].
CO-EXPRESSION OF PCNA AND PTH/PTHrP RECEPTOR IN
THE REGENERATING TISSUE OF ARTICULAR CARTILAGE
DEFECTS
In our previous study7, we reported that chondrogenic re-
pair could successfully resurface full-thickness defects of
articular cartilage with hyaline cartilage, when active expan-
sion of prechondrogenic cells was maintained in the center
of the defects, prior to cartilage formation during the early
stage of the repair process. Thus, at this early stage, the ac-
cumulation of PCNA-positive cells in the defect cavities was
indicative of cartilaginous repair7,8. In this current study, we
compared the distribution of PTH/PTHrP receptor-positive
cells to PCNA-positive proliferating cells in the defects by
double immunostaining.
In the reparative tissue in the control defect group, almost
90% of the spindle-shaped cells were PTH/PTHrP receptor-
positive at 1 week post-injury (Table II). In addition, almost
all of the PCNA-positive proliferating cells were among the
PTH/PTHrP receptor-positive cell population, and thus the
majority of the spindle-shaped cells in the defects were dou-
ble positive for PTH/PTHrP and PCNA [Fig. 5(A) and Table
II]. In the 2-week PTH-treated group at the end of the treat-
ment period [Fig. 5(B)], the distribution pattern of these cells
in the defect cavities appeared to be similar to that of the
control defects; 95% of the cells in the reparative tissue
were PTH/PTHrP receptor-positive and more than 50%
were proliferating, as indicated by positive PCNA staining.
On the other hand, less than 0.8% of these cells were
PTH/PTHrP receptor-negative and PCNA-positive (Table II).
In contrast to both the control and 2-week PTH groups,
when the articular cartilage defects were treated withhPTH(1e84) for 4 weeks, the cavities were mainly ﬁlled
with PTH/PTHrP receptor-negative cells. Almost all of these
PTH/PTHrP receptor-negative cells were also PCNA-nega-
tive, and hence non-proliferating, and were localized at the
center and in the surface of the defects [Fig. 5(C)]. Thus, on
average, about 70% of the cells that ﬁlled the defect cavities
in this group were detected as PTH/PTHrP receptor and
PCNA double-negative (Table II). The PTH/PTHrP recep-
tor-positive cells in this group were localized mainly at the
periphery of the defects, regardless of their PCNA status.
There were also no signiﬁcant changes in the staining pat-
terns in these defects until 12 weeks post-injury (data not
shown).
Few PTH/PTHrP receptor-positive or PCNA-positive cells
were observed in the 3-mm defects of the 4-week PTH
group and the staining patterns of the cells ﬁlling these cav-
ities were essentially identical to the cells in 5-mm-diameter
defects that were resurfaced only with ﬁbrous tissue. As
observed for the 3-mm 4-week PTH cavities, more than
70%of cells ﬁlling the 5-mmdefects were PTH/PTHrP recep-
tor andPCNAdouble-negative [Fig. 5(D) andTable II]. On the
other hand, when cartilaginous repair was induced by the
administration of FGF (50 pg/h) in these larger cavities, the
PTH/PTHrP receptor and PCNA double-negative cells mark-
edly decreased to an average of about 6.2% of the popula-
tion. Moreover, the population of PTH/PTHrP receptor-
positive cells represented about 93% of the total cells in the
reparative tissue of these 5-mm defects at 1 week following
FGF administration and more than 50% of these were
PCNA-positive proliferating cells [Fig. 5(E) and Table II].
Discussion
In a rabbit model of articular cartilage defects, smaller cy-
lindrical full-thickness defects (3 mm in diameter) sponta-
neously regenerate surfacing cartilage1,4. Within a few days
after creation of these cavities, ﬁbrous arcades are estab-
lished between the surface edges across the defect, and
this promotes the ingrowth of mesenchymal cells along
the long axes from the bone marrow. Within 1 week,
PCNA-positive cells occupy the majority of these defect
cavities. As we previously reported7,8, the active expansion
and maintenance of chondroprogenitor cells in the early
stages of repair is critical for the successful cartilaginous
regeneration of these defects (Table II). Once safranin-O-
positive cartilaginous tissue ﬁlls the defects at 2 weeks
post-injury [Fig. 2(A and B)], these cavities are eventually
resurfaced by cartilage within 8 weeks through the replace-
ment of cartilage by bone at the depth of the defect [Fig. 2(C
and D)].Table II
Expression of the PTH/PTHrP receptor in the PCNA-positive or negative spindle-shaped cells*
PTH/PTHrP receptor-positive cells (%) PTH/PTHrP receptor-negative cells (%)
PCNA-positive PCNA-negative cells PCNA-positive PCNA-negative cells
3-mm-diameter defects
Control group at 1 week 52.6 2.6 35.4 2.0 1.2 1.5 12.8 2.4
PTH 2-week group at 2 weeks 55.3 4.1 39.2 3.8 0.8 3.6 4.7 3.8
PTH 4-week group at 4 weeks 13.2 2.1 16.5 4.1 0.5 3.3 68.8 1.9
5-mm-diameter defects
Control group at 1 week 13.1 6.7 14.0 4.4 0.2 1.3 72.7 7.5
FGF-treated group at 1 week 52.3 10.5 40.2 11.8 1.3 4.1 6.2 5.6
*Each staining type of cells was counted in a total of 180 ﬁelds using three sections for each animal at a magniﬁcation of 400. Values are
meansSD for ﬁve animals.
950 H. Mizuta et al.: PTH/PTHrP receptor expression in chondrogenic cellsFig. 5. Double immunostaining analysis of the PTH/PTHrP receptor and PCNA in the reparative tissue of the articular cartilage defects. Panel
A shows ﬁbrous regenerative tissue ﬁlling the center of the 3-mm-diameter control defects that had been administered with saline alone at 1
week post-injury. Panels B and C indicate the reparative tissue in the 3-mm-diameter defects at the end of the 25 ng/h hPTH (1e84) treat-
ments at 2 and 4 weeks, respectively. In comparison, 5-mm-diameter defects were administered with either with saline alone (D) or with
50 pg/h FGF-2 (E) for 1 week. PCNA was stained red with ALP-Vector Red and PTH/PTHrP receptor was stained brown with DAB. The
sections were counterstained with hematoxylin. Bar, 50 mm.There is now an accumulating body of evidence to indicate
that PTH/PTHrP receptor signaling acts on both proliferating
and prehypertrophic chondrocytes and participates in their
proper transition to the hypertrophic stage of differentiation
(the late-phase differentiation of chondrocytes)9e11,26. The
PTH/PTHrP receptor slows down the progression of chon-
drocyte differentiation by preventing the proliferating cells
from immature cell cycle exit14,27. However, by in vitro analy-
sis we previously demonstrated that PTH/PTHrP receptor
expression is induced by the commitment of early-phase
chondrogenic differentiation and that the activation of PTH/
PTHrP receptor signaling markedly inhibits this early-phase
differentiation of chondroprogenitor cells in a reversible
manner15,18.
In our present study, the activation of PTH/PTHrP recep-
tor signaling resulted in the inhibition of the chondrogenic
differentiation, which would normally be expected to occur
in the defects within 2 weeks19. At the cessation of PTH
treatment at 2 weeks post-injury, the defects were ﬁlled
with only undifferentiated mesenchymal cells (Fig. 2).
Over 90% of the migrating cells retained their responsive-
ness to PTH/PTHrP in the defects, as revealed by the
expression of the cognitive receptor (Fig. 4). At the center
of the defect cavities in 2-week PTH-treated animals
(Fig. 2), almost all of the cells were PTH/PTHrP receptor-
and PCNA double-positive (Fig. 5). Table II shows that
the double-positive cells represent a major cell sub-type in
the cavity space. However, overt chondrogenesis was
clearly abrogated during PTH administration as within 2
weeks after their release from PTH/PTHrP receptor activa-
tion, the migratory cells in the defects began to execute
chondrogenic differentiation and cartilaginous repair at the
rate similar to the controls (Fig. 3).
Signiﬁcantly, these results in vivo were compatible with
our in vitro ﬁndings that the activation of PTH/PTHrP recep-
tor signaling inhibits the early-phase differentiation of chon-
droprogenitor cells in a reversible manner18. Sakamoto
et al. previously reported that ectopic cartilage formation
occurs within the metaphyseal region of the tibia in chondro-
cyte-speciﬁc knockout mice of GSa, a downstreameffector of the PTH/PTHrP receptor28. This suggests that
there was a release of progenitor cells in perichondrium
from the inhibitory action of PTH/PTHrP signaling that
resulted in the successful induction of the early-phase
differentiation of cells.
The prolonged hPTH(1e84) treatment for a period of 4
weeks resulted in a completely irreversible loss of regener-
ative repair in cavities of these defects (Figs. 2 and 3). Cells
at the center of the defects (Fig. 2) had also irreversibly lost
PTH/PTHrP receptor expression, which could not be recov-
ered even after many weeks following the withdrawal of
PTH administration (Figs. 4 and 5). Furthermore, PTH/
PTHrP receptor/PCNA double-negative cells constituted
a major proportion of the cells in the defect cavities after
the prolonged 4-week PTH treatment of 3-mm-diameter
defects (Table II). Thus, the mesenchymal cells that had
migrated to the site of the defects were chondrogenesis-
competent for only a limited time-span of within 2 weeks
and lose their regenerative capacity after prolonged PTH
treatment. These cells are thus transformed from a chondro-
genic to a ﬁbroblastic phenotype.
These observations are compatible with the previous
ﬁndings by Lewinson et al. who demonstrated that continu-
ous exposure to PTH for 24 h did not affect the chondro-
genic capacity of progenitor cells in condylar cartilage in
organ cultures of neonatal mice29. However, a prolonged
exposure to PTH for 12 days resulted in morphological
changes, a reduction in the extracellular matrix and cellular
breakdown in the chondroprogenitor zone29. Gonzalez et al.
also reported that a high circulation level of PTH during
hyperparathyroidism produces chronic ﬁbrosis in bone mar-
row, in which PTH suppresses the differentiation of progen-
itor cells30. Here we have shown that there is a close
association between chondrogenic capacity and PTH/
PTHrP receptor expression in the reparative tissue of
full-thickness articular cartilage defects, indicating that this
signaling pathway is required for the regulation of this differ-
entiation process.
Self-renewing mesenchymal cells derived from bone
marrow are the major contributors to the regenerative repair
951Osteoarthritis and Cartilage Vol. 14, No. 9of articular cartilage1,7,31. Isolation and expansion of adult
mesenchymal stem cells is critically important for the thera-
peutic application of these cells in regenerative medicine.
Recent genetic analysis began to deﬁne osteo-chondropro-
genitors in limb bud during development32,33. For the
establishment of chondrogenic cell-therapy, it is critically
important to elucidate how the fate of multipotential stem
cells is restricted during migration and concentration at
the site of repair in vivo. However, it is still difﬁcult to deﬁne
adult mesenchymal stem cells and their subpopulations at
a molecular level because of the lack of a complete set of
cell-surface markers that represent functional characteris-
tics of the cells34,35. Although the evaluation of the chondro-
genic potential of marrow-derived cells that have been
sorted by reactivity to antibodies against the PTH/PTHrP
receptor needs to be further studied, this may serve as
a useful marker for chondroprogenitor cells in combination
with other markers.
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